Biomarkers in medicine · 2025
Hepatic steatosis/fibrosis related biomarkers in patients with metabolic dysfunction-associated steatotic liver disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Peng Zhi, Wang Zijin, Wang Juan, Li Xuefeng
Аннотация
AIMS: To explore hepatic steatosis and fibrosis related biomarkers in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
PATIENTS AND METHODS: Total 158 patients with MASLD were tested with Fibroscan to measure hepatic steatosis value (CAP value) and liver fibrosis value (E value), and divided into mild group (31 cases), moderate (49 cases), and severe fatty liver group (78 cases) according to CAP value; no fibrosis group (106 cases), early fibrosis group (38 cases), and advanced fibrosis and cirrhosis group (14 cases) according to E value.
RESULTS: E value was negatively correlated with CHOL and LDL, and CAP value was positively correlated with LDL. TG, CHOL and LDL levels in severe fatty liver group were significantly higher than those in mild fatty liver group; TG and LDL levels in moderate fatty liver group were higher than those in mild fatty liver group. TG level in early fibrosis group was significantly higher than that in advanced fibrosis and cirrhosis group.
CONCLUSION: With the aggravation of hyperlipidemia, hepatic steatosis increases; with the aggravation of liver fibrosis, TG level decreases. Lipid metabolism worsens with the degree of steatosis. LDL is related to the severity of hepatic steatosis and fibrosis.
PATIENTS AND METHODS: Total 158 patients with MASLD were tested with Fibroscan to measure hepatic steatosis value (CAP value) and liver fibrosis value (E value), and divided into mild group (31 cases), moderate (49 cases), and severe fatty liver group (78 cases) according to CAP value; no fibrosis group (106 cases), early fibrosis group (38 cases), and advanced fibrosis and cirrhosis group (14 cases) according to E value.
RESULTS: E value was negatively correlated with CHOL and LDL, and CAP value was positively correlated with LDL. TG, CHOL and LDL levels in severe fatty liver group were significantly higher than those in mild fatty liver group; TG and LDL levels in moderate fatty liver group were higher than those in mild fatty liver group. TG level in early fibrosis group was significantly higher than that in advanced fibrosis and cirrhosis group.
CONCLUSION: With the aggravation of hyperlipidemia, hepatic steatosis increases; with the aggravation of liver fibrosis, TG level decreases. Lipid metabolism worsens with the degree of steatosis. LDL is related to the severity of hepatic steatosis and fibrosis.